Amsterdam, The Netherlands, April 7, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nominate Dr. Robert Soiffer and Mr. Berndt Modig to be appointed as new members of the Supervisory Board.
Dr. Robert Soiffer has worked in professional medical practice for more than 30 years, specifically in the field of hematologic malignancies and stem cell/bone marrow transplantations. Dr. Soiffer is Professor of Medicine at the Harvard Medical School, Chief of the Division of Hematologic Malignancies at the Dana-Farber Cancer Institute (which is part of the Harvard Medical School) and Co-director of the Adult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute. Dr. Soiffer is Chair Elect of the Advisory Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), serves on the Board of Directors for the National Marrow Donor Program Be the Match Registry and has served as President of the American Society of Blood and Marrow Transplantation (ASBMT). Dr. Soiffer graduated from the New York University School of Medicine and completed his residency in internal medicine at Brigham and Women’s Hospital where he was also Chief Medical Resident before joining the Dana-Farber Cancer Institute, after completing a medical oncology fellowship.
Mr. Berndt Modig has more than 30 years of professional international experience in finance, including operations management and audit committee roles. He has served as Chief Financial Officer of Prosensa Holding N.V. and as Chief Financial Officer at Jerini AG. Mr. Modig is currently serving on the boards of Axovant Sciences Ltd., Auris Medical AG and Affimed N.V. and is CEO of Pharvaris B.V. Mr. Modig holds a bachelor’s degree in business administration, economics and German from the University of Lund, Sweden and an M.B.A. degree from INSEAD, Fontainebleau, France and is a Certified Public Accountant.
Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma, commented: “We are delighted to welcome both Robert and Berndt to our Supervisory Board. They are both highly respected, well connected professionals with very relevant experience. Their expertise gained from working within the biotechnology and pharmaceutical sectors across both Europe and the US will be invaluable to Kiadis Pharma as we continue to build momentum following the recent announcement of positive results on the primary endpoint of our Phase II trial with our lead product ATIR101™.”
